uniQure N.V. (NASDAQ: QURE) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
43.68
-0.38-0.86%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -4.04 | Insider Own | 3.43% | Shs Outstand | 69.37M | Perf Week | 19.15% |
| Market Cap | 3.03B | Forward P/E | - | EPS next Y | -3.04 | Insider Trans | -22.67% | Shs Float | 62.17M | Perf Month | 5.61% |
| Enterprise Value | 2.28B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 16.68% | Perf Quarter | 111.22% |
| Income | -253.00M | P/S | 151.50 | EPS this Y | 3.46% | Inst Trans | - | Short Ratio | 4.80 | Perf Half Y | 76.84% |
| Sales | 20.00M | P/B | 9.35 | EPS next Y | 22.02% | ROA | -25.60% | Short Interest | 10.37M | Perf YTD | 82.53% |
| Book/sh | 4.67 | P/C | 3.74 | EPS next 5Y | - | ROE | -111.96% | 52W High | 71.50 -38.91% | Perf Year | 218.83% |
| Cash/sh | 11.68 | P/FCF | - | EPS past 3/5Y | - | ROIC | -22.48% | 52W Low | 8.73 400.34% | Perf 3Y | 343.00% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -46.76% -15.89% | Gross Margin | 22.79% | Volatility | 6.90% 5.64% | Perf 5Y | 54.73% |
| Dividend TTM | - | EV/Sales | 114.00 | EPS Y/Y TTM | 17.89% | Oper. Margin | -1089.06% | ATR (14) | 2.64 | Perf 10Y | 521.34% |
| Dividend Ex-Date | - | Quick Ratio | 10.01 | Sales Y/Y TTM | -25.93% | Profit Margin | -1350.73% | RSI (14) | 60.03 | Recom | 2.11 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.01 | EPS Q/Q | -3.66% | SMA20 | 6.42% | Beta | 0.84 | Target Price | 57.50 |
| Payout | 0.00% | Debt/Eq | 2.70 | Sales Q/Q | 20.00% | SMA50 | 16.53% | Rel Volume | 0.60 | Prev Close | 44.06 |
| Employees | 221 | LT Debt/Eq | 2.68 | Earnings | Nov 09 | SMA200 | 53.96% | Avg Volume | 2.16M | Price | 43.68 |
| IPO Date | Feb 05, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 1.71% -31.56% | Net Debt/EBITDA | 1.93 | Volume | 1,286,800 | Change | -0.86% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-30-26 | Reiterated | Barclays | Overweight | $65 → $60 |
| Jul-30-26 | Upgrade | Wolfe Research | Peer Perform → Outperform | |
| Jun-29-26 | Reiterated | HC Wainwright & Co. | Buy | $50 → $80 |
| Jun-25-26 | Reiterated | Mizuho | Outperform | $33 → $68 |
| Jun-18-26 | Upgrade | Barclays | Equal Weight → Overweight | $31 → $65 |
| Jun-18-26 | Reiterated | Goldman Sachs | Neutral | $10 → $46 |
| Jun-18-26 | Reiterated | Leerink Partners | Outperform | $35 → $70 |
| Jun-18-26 | Reiterated | RBC Capital | Outperform | $35 → $65 |
| Jun-17-26 | Reiterated | Cantor Fitzgerald | Neutral | $47 → $61 |
| May-06-26 | Reiterated | HC Wainwright & Co. | Buy | $70 → $50 |
Latest News
Jul-30-26
08:05AM
Jul-29-26
01:05PM
uniQure Q2 Earnings Call Highlightsmarketbeat.com
09:31AM
07:05AM
Jul-22-26
Jul-17-26
03:26PM
Jul-01-26
Jun-29-26
Jun-29-2609:05AM
Jun-26-26
Jun-25-26
Jun-25-2608:10PM
Company
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 20 | 16 | 27 | 16 | 106 | 524 | 38 | 7 | 11 | |
| Cost of Goods Sold Incl. D&A | 13 | 2 | 18 | 14 | 3 | 25 | 122 | 0 | 73 | |
| Gross Profit | 3 | 14 | 9 | 2 | 103 | 499 | -85 | 7 | -62 | |
| Selling, General and Administrative Excl. Other | 75 | 65 | 51 | 73 | 55 | 56 | 43 | 34 | 25 | |
| Research and Development | 131 | 141 | 144 | 215 | 198 | 144 | 122 | 95 | 75 | |
| Other Operating Expense | 1 | -4 | -2 | -3 | -7 | -12 | -124 | -1 | 0 | |
| Operating Income | -203 | -188 | -184 | -283 | -143 | 311 | -125 | -121 | -88 | |
| Interest Expense | 60 | 62 | 64 | 42 | 12 | 7 | 4 | 4 | 2 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 18 | 56 | 11 | 18 | 27 | 30 | -12 | 1 | 7 | |
| Net Income Before Taxes | -245 | -193 | -237 | -307 | -128 | 333 | -141 | -124 | -83 | |
| Income Taxes | 7 | 6 | 2 | 2 | -1 | 3 | -16 | 0 | 0 | |
| Consolidated Net Income | -253 | -199 | -240 | -308 | -127 | 330 | -125 | -124 | -83 | |
| Net Income From Continuing Operations | -253 | -199 | -240 | -308 | -127 | 330 | -125 | -124 | -83 | |
| Net Income | -253 | -199 | -240 | -308 | -127 | 330 | -125 | -124 | -83 | |
| EPS (Recurring) | -4.04 | -3.46 | -4.92 | -6.47 | -2.71 | 7.17 | -2.81 | -3.20 | -2.34 | |
| EPS (Basic, Before Extraordinaries) | -4.04 | -3.46 | -4.92 | -6.47 | -2.71 | 7.17 | -2.81 | -3.20 | -2.34 | |
| EPS (Diluted) | -4.04 | -3.46 | -4.92 | -6.47 | -2.71 | 7.04 | -2.81 | -3.20 | -2.34 | |
| EBITDA | -181 | -117 | -161 | -253 | -108 | 319 | -127 | -114 | -74 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | 2.95 | — | — | — | |
| Price To Sales Ratio | 144.14 | 86.75 | 32.05 | 20.31 | 10.05 | 1.82 | 41.83 | 409.49 | 94.32 | |
| Gross Margin | 15.00 | 87.50 | 33.33 | 12.50 | 97.17 | 95.23 | -223.68 | 100.00 | -563.64 | |
| Operating Margin | -1,015.00 | -1,175.00 | -681.48 | -1,768.75 | -134.91 | 59.35 | -328.95 | -1,728.57 | -800.00 | |
| Net Margin | -1,265.00 | -1,243.75 | -888.89 | -1,925.00 | -119.81 | 62.98 | -328.95 | -1,771.43 | -754.55 | |
| Shares Outstanding | 66 | 58 | 49 | 48 | 47 | 46 | 44 | 40 | 36 | |
| Market Capitalization | 2,883 | 1,388 | 865 | 325 | 1,065 | 954 | 1,590 | 2,866 | 1,038 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director | Jul 02 '26 | Sale | 45.16 | 21,082 | 952,051 | 519,227 | Jul 07 |
| Kapusta Matthew C | CEO, Managing Director | Jul 02 '26 | Option Exercise | 19.39 | 21,082 | 408,780 | 540,309 | Jul 07 |
| Kaye Jack | Director | Jun 30 '26 | Option Exercise | 23.44 | 21,167 | 496,230 | 43,056 | Jul 02 |
| Abi-Saab Walid | Chief Medical Officer | Jun 30 '26 | Option Exercise | 5.59 | 10,000 | 55,900 | 178,235 | Jul 02 |
| Kaye Jack | Director | Jun 30 '26 | Sale | 46.44 | 21,167 | 983,030 | 25,996 | Jul 02 |
| Abi-Saab Walid | Chief Medical Officer | Jun 30 '26 | Sale | 46.42 | 30,000 | 1,392,600 | 148,235 | Jul 02 |
| Abi-Saab Walid | Chief Medical Officer | Jun 26 '26 | Sale | 46.86 | 1,434 | 67,197 | 168,235 | Jun 30 |
| Kapusta Matthew C | CEO, Managing Director | Jun 25 '26 | Option Exercise | 31.71 | 28,716 | 910,584 | 547,943 | Jun 26 |
| Kapusta Matthew C | CEO, Managing Director | Jun 25 '26 | Sale | 50.02 | 28,716 | 1,436,374 | 519,227 | Jun 26 |
| Kapusta Matthew C | CEO, Managing Director | Jun 24 '26 | Sale | 50.00 | 6,696 | 334,800 | 519,227 | Jun 26 |
| Kapusta Matthew C | CEO, Managing Director | Jun 24 '26 | Option Exercise | 31.71 | 4,128 | 130,899 | 525,923 | Jun 26 |
| Kapusta Matthew C | CEO, Managing Director | Jun 18 '26 | Sale | 50.00 | 41,671 | 2,083,550 | 521,795 | Jun 22 |
| Kapusta Matthew C | CEO, Managing Director | Jun 18 '26 | Option Exercise | 31.71 | 4,656 | 147,642 | 563,466 | Jun 22 |
| Kapusta Matthew C | CEO, Managing Director | Jun 17 '26 | Sale | 44.32 | 164,429 | 7,288,061 | 558,810 | Jun 22 |
| Kapusta Matthew C | CEO, Managing Director | Jun 17 '26 | Option Exercise | 19.39 | 62,581 | 1,213,446 | 723,239 | Jun 22 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.